Lobeglitazone vs Pioglitazone (JT-001)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: PPAR-gamma · full Type 2 Diabetes pipeline
Lobeglitazone · Duvie
Marketed by Chong Kun Dang Pharmaceutical and partners
NCT02002611 · Phase 1 · completed
Every participant received both lobeglitazone and warfarin, so there is no separate group showing what would have happened without lobeglitazone, and nobody was blinded to treatment. The measures collected were drug-level readings for a drug-interaction check, not a symptom or disease-based result, so this trial offers only limited evidence about lobeglitazone's own effects.
Next expected readout: September 2029 · NCT07108985 (registry estimate)
Reported efficacy
Change from baseline in Glycosylated Hemoglobin (HbA1c) (Baseline, 24 weeks): HbA1c change at 24 weeks vs placebo (Study 1, empagliflozin 10 mg plus metformin background): -0.71% (95% CI -0.88 to -0.55), p<0.001. The publication reports Study 2 (empagliflozin 25 mg background, NCT03627182) separately. (met)
Result source: NCT03739125
Pioglitazone (JT-001)
Developed by Jeil Pharmaceutical
NCT05101135 · Phase 3 · status unknown
This randomized, double-blind, placebo-controlled trial enrolled 256 patients and measured change in HbA1c, a standard diabetes efficacy measure, at 24 weeks. JT-001 significantly reduced HbA1c versus placebo (p<0.0001), and more patients on JT-001 reached HbA1c targets of below 7% and 6.5%.
ClinicalTrials.gov still shows the planned enrollment of 256; the published report gives 262 randomized (131 per arm).
Reported efficacy
Changes in HbA1c (24th Week): JT-001 (pioglitazone 15mg) add-on vs placebo, week 24 HbA1c change: -0.47% (95% CI -0.61 to -0.33), P<0.0001. HbA1c<7% achieved: 56.8% vs 28%; HbA1c<6.5%: 23.2% vs 9.6% (P<0.0001 for all). (met)
Result source: NCT05101135
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lobeglitazone | Pioglitazone (JT-001) |
|---|---|---|
| HbA1c, change | —Not posted · NCT01106131 | —Not reported |
| Body weight, change (kg) | —Not posted · NCT01106131 | —Not reported |
| HbA1c below 7% | —Not posted · NCT01106131 | —Not reported |
| Fasting plasma glucose, change | —Not posted · NCT01106131 | —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT01106131 | —Not reported |
HbA1c, change
- Lobeglitazone
- —Not posted · NCT01106131
- Pioglitazone (JT-001)
- —Not reported
Body weight, change (kg)
- Lobeglitazone
- —Not posted · NCT01106131
- Pioglitazone (JT-001)
- —Not reported
HbA1c below 7%
- Lobeglitazone
- —Not posted · NCT01106131
- Pioglitazone (JT-001)
- —Not reported
Fasting plasma glucose, change
- Lobeglitazone
- —Not posted · NCT01106131
- Pioglitazone (JT-001)
- —Not reported
3-point MACE (% with event)
- Lobeglitazone
- —Not posted · NCT01106131
- Pioglitazone (JT-001)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lobeglitazone's landscape · Pioglitazone (JT-001)'s landscape